274 related articles for article (PubMed ID: 1883848)
1. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
Steinsapir J; Mora G; Muldoon TG
Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of antiandrogens in the rat.
Burton S; Trachtenberg J
J Urol; 1986 Oct; 136(4):932-5. PubMed ID: 3761464
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
[TBL] [Abstract][Full Text] [Related]
4. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins.
Ayub M; Levell MJ
J Steroid Biochem; 1989 Aug; 33(2):251-5. PubMed ID: 2788775
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of rat testicular 17 alpha-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro.
Ayub M; Levell MJ
J Steroid Biochem; 1987 Jul; 28(1):43-7. PubMed ID: 2956461
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
Rennie PS; Bruchovsky N; Goldenberg SL; Lawson D; Fletcher T; Foekens JA
J Urol; 1988 Jun; 139(6):1337-42. PubMed ID: 2967378
[TBL] [Abstract][Full Text] [Related]
7. The effect of antiandrogens and stilboestrol on the cytosol receptor in rat prostate.
Ghanadian R; Smith CB; Williams G; Chisholm GD
Br J Urol; 1977; 49(7):695-700. PubMed ID: 74269
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Warriar N; Pagé N; Koutsilieris M; Govindan MV
Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
10. Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei.
Karvonen U; Jänne OA; Palvimo JJ
FEBS Lett; 2002 Jul; 523(1-3):43-7. PubMed ID: 12123801
[TBL] [Abstract][Full Text] [Related]
11. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
12. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of androgen binding in human foreskin fibroblasts by antiandrogens.
Brown TR; Rothwell SW; Sultan C; Migeon CJ
Steroids; 1981 Jun; 37(6):635-48. PubMed ID: 6457421
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
15. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
Furr BJ
Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
[No Abstract] [Full Text] [Related]
16. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection.
Nguyen TV; Yao M; Pike CJ
Endocrinology; 2007 Jun; 148(6):2936-43. PubMed ID: 17347309
[TBL] [Abstract][Full Text] [Related]
17. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
18. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL
Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor antagonists (antiandrogens): structure-activity relationships.
Singh SM; Gauthier S; Labrie F
Curr Med Chem; 2000 Feb; 7(2):211-47. PubMed ID: 10637363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
